Literature DB >> 2765636

Simple parametric and nonparametric models for excess and relative mortality.

P K Andersen1, M Vaeth.   

Abstract

This paper studies two classes of hazard-rate-based models for the mortality in a group of individuals taking normal life expectancy into account. In a multiplicative hazard model, the estimate for the relative mortality generalises the standardised mortality ratio, and the adequacy of a model with constant relative mortality can be tested using a type of total time on test statistic. In an additive hazard model, continuous-time generalisations of a "corrected" survival curve and a "normal" survival curve are obtained, and the adequacy of a model with constant excess mortality can again be tested using a type of total time on test statistic. A model including both the multiplicative hazard model and the additive hazard model is briefly considered. The use of the models is illustrated on a set of data concerning survival after operation for malignant melanoma.

Entities:  

Keywords:  Demographic Factors; Denmark; Developed Countries; Estimation Technics; Europe; Length Of Life; Life Expectancy; Mathematical Model; Models, Theoretical; Mortality; Northern Europe; Population; Population Dynamics; Research Methodology; Scandinavia

Mesh:

Year:  1989        PMID: 2765636

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  24 in total

1.  The attractiveness of an additive hazard model: an example from medical demography.

Authors:  O Kravdal
Journal:  Eur J Popul       Date:  1997-03

2.  Adjusting and comparing survival curves by means of an additive risk model.

Authors:  P H Zahl; O O Aalen
Journal:  Lifetime Data Anal       Date:  1998       Impact factor: 1.588

Review 3.  Historical controls and modern survival analysis.

Authors:  N Keiding
Journal:  Lifetime Data Anal       Date:  1995       Impact factor: 1.588

4.  Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism.

Authors:  Mary Eapen; Kwang Woo Ahn; Paul J Orchard; Morton J Cowan; Stella M Davies; Anders Fasth; Anna Hassebroek; Mouhab Ayas; Carmem Bonfim; Tracey A O'Brien; Thomas G Gross; Mitchell Horwitz; Edwin Horwitz; Neena Kapoor; Joanne Kurtzberg; Navneet Majhail; Olle Ringden; Paul Szabolcs; Paul Veys; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2012-03-16       Impact factor: 5.742

5.  Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.

Authors:  John M Goldman; Navneet S Majhail; John P Klein; Zhiwei Wang; Kathleen A Sobocinski; Mukta Arora; Mary M Horowitz; J Douglas Rizzo
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

6.  Estimation of covariate effects with current status data and differential mortality.

Authors:  Alberto Palloni; Jason R Thomas
Journal:  Demography       Date:  2013-04

7.  Mark-specific additive hazards regression with continuous marks.

Authors:  Dongxiao Han; Liuquan Sun; Yanqing Sun; Li Qi
Journal:  Lifetime Data Anal       Date:  2016-05-11       Impact factor: 1.588

8.  High probability of long-term survival in 2-year survivors of autologous hematopoietic cell transplantation for AML in first or second CR.

Authors:  N S Majhail; R Bajorunaite; H M Lazarus; Z Wang; J P Klein; M J Zhang; J D Rizzo
Journal:  Bone Marrow Transplant       Date:  2010-05-17       Impact factor: 5.483

9.  Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma.

Authors:  Navneet S Majhail; Ruta Bajorunaite; Hillard M Lazarus; Zhiwei Wang; John P Klein; Mei-Jie Zhang; J Douglas Rizzo
Journal:  Br J Haematol       Date:  2009-07-01       Impact factor: 6.998

10.  Dynamic regression hazards models for relative survival.

Authors:  Giuliana Cortese; Thomas H Scheike
Journal:  Stat Med       Date:  2008-08-15       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.